All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Breast-Conserving Therapy Outcomes Deemed Similar to Mastectomy

September 6th 2011

Women age 40 and younger with breast cancer experience similar outcomes in local recurrence and survival rates whether they undergo BCT or a mastectomy.

Yoga Research Study 1: Peaceful Play Yoga

September 6th 2011

Offering yoga to children living with cancer is an exciting opportunity for registered nurses to learn about and to practice.

Wrong-site Surgery

September 6th 2011

Wrong-site surgery is still occurring despite wide adoption of prevention strategies.

Xalkori: A Revolution in Lung Cancer Treatment

August 30th 2011

While smoking and lung cancer have always been closely linked, recent advances in research have begun to unravel the genetic code behind the disease.

FDA Approves Crizotinib for Late-Stage Non-Small Cell Lung Cancer

August 26th 2011

On Friday, August 26, 2011, the FDA approved crizotinib (Xalkori) to treat ALK-positive patients with late-stage nonâ€“small cell lung cancer (NSCLC).

Importance of Yoga Research

August 22nd 2011

Scientific research documenting the effects of yoga practice on the health of people living with cancer is an exciting world to explore.

Predicting Secondary Cancers in Hodgkin Lymphoma Survivors

August 22nd 2011

Two small genetic variations predict which patients are most likely to develop second cancers.

FDA Approves Brentuximab Vedotin for 2 Types of Lymphoma

August 19th 2011

The FDA announced that brentuximab vedotin has been approved for the treatment of Hodgkin lymphoma and systemic anaplastic large cell lymphoma.

Vemurafenib Receives Approval for Metastatic Melanoma

August 17th 2011

The FDA approved vemurafenib and a companion diagnostic test in a move that was hailed as an advance for both patients and personalized medicine.

Electronic Prescriptions

August 15th 2011

Prescriptions sent electronically are just as likely to contain errors as handwritten ones.

Patients' Perceptions and Medicare Data

August 8th 2011

What patients think about quality of care does not always correlate with objective measures.

Computer-Aided Breast Cancer Detection

August 4th 2011

Recent study findings raise questions about how well computers interpret mammograms.

Checking in With You

August 3rd 2011

Looking back and examining previous lessons from the Yoga Blog.

Weighing the Risk Versus Benefits of Transthoracic Needle Biopsies in Lung Cancer

August 2nd 2011

A new study found that biopsies of lung nodules found during a CT scan may be unnecessary and dangerous.

Judge Rules BRCA Genes Can Be Patented, Overturning Previous Decision

August 1st 2011

On July, 29, 2011, a US appeals court sided with Myriad Genetics, Inc's patents on the BRCA1 and BRCA2 genes.

Researchers Identify Gene Involved in DNA Repair From UVB Damage

July 29th 2011

The tumor suppressor gene PTEN has been linked to the removal of DNA damage from UVB radiation, a major risk factor in the development of skin cancer.

Sentinel Lymph Node Test Has No Effect on Overall Survival in Women With Early-Stage Breast Cancer

July 28th 2011

It had been thought that removing the sentinel node and the surrounding lymph nodes would improve survival rates.

3 New Genetic Mutations Establish Hereditary Link in Esophageal Cancer

July 27th 2011

Three new genetic mutations have been identified in patients with Barrett's esophagus (BE) and esophageal adenocarcinoma (EAC).

Flip Flops, Baseball Caps, and Skin Cancer

July 27th 2011

Sun exposure to usually-covered skin is yet another risk for skin cancer.

Erlotinib Extends PFS in EGFR-Positive Lung Cancer

July 25th 2011

Findings from a randomized phase III trial in China suggest erlotinib is suitable for first-line treatment in patients with EGFR mutation-positive NSCLC.